预约演示
更新于：2025-09-09
Bilastine
比拉斯汀
更新于：2025-09-09
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37N3O3 |
InChIKeyACCMWZWAEFYUGZ-UHFFFAOYSA-N |
CAS号202189-78-4 |
关联
136
项与 比拉斯汀 相关的临床试验TCTR20250619004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Bilastine 20 mg Tablets and Reference Product (BILAXTEN 20 mg tablets) in Healthy Thai Volunteers under Fasting Conditions
TCTR20250226007
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Bilastine 20 mg Tablets and Reference Product (Bilaxten) in Healthy Thai Volunteers under Fasting Conditions
CTR20252453
比拉斯汀口服溶液人体生物等效性试验
100 项与 比拉斯汀 相关的临床结果
登录后查看更多信息
100 项与 比拉斯汀 相关的转化医学
登录后查看更多信息
100 项与 比拉斯汀 相关的专利（医药）
登录后查看更多信息
306
项与 比拉斯汀 相关的文献（医药）2025-09-01WATER RESEARCH
Biological ion exchange for natural organic matter removal from drinking water
Review
作者: Zimmermann, Karl ; Chen, William ; Barbeau, Benoit ; Schoutteten, Klaas ; Liu, Zhen ; Mohseni, Madjid ; Bérubé, Pierre
The state of knowledge for ion exchange (IEX) drinking water filters is updated in this review with new understandings that allow for dramatically extending filter run length from days to months or years between regenerations. By simply allowing IEX filters to operate past chloride exhaustion, water practitioners can take advantage of continuing natural organic matter removal through a combination of sulphate-based secondary IEX and bio-removal mechanisms. Herein, we review literature and add new findings to describe all three mechanisms and their relative contributions, and provide insights to design and operate biological IEX, or 'BIEX', drinking water filters. Generalizing with new and literature data on 34 case studies from three continents, the chloride-based primary IEX lasted 3,100 bed volumes (BV) with 69 % DOC removal, while sulphate-based secondary IEX provided an additional 24,400 BV of run length with 51 % DOC removal. Bio-removal provided 5-10 % DOC removal irrespective of the IEX mechanism, although bio-removal mechanisms are less understood. Treatment performance depended on operating conditions and influent water quality, specifically the ratio of [Total Anions]-to-[DOC] concentrations in influent water, for which a linear relationship was described as [%DOCremoval]=0.57-0.0123×[TotalAnions:DOCratio]. Two models are shared to estimate filter run length either from empirical data or by minimizing the operating expenses (OPEX). While OPEX was influenced by either brine disposal or resin replacement costs depending on the system's scale, the total costs were dominated by capital expenses. Meanwhile, resin lifetime was influenced by filter run length and regeneration, and so cleaning approaches are discussed including caustic or citric acid. Understanding the mechanisms for DOC removal and informed with empirical models to predict treatment performance and run length, our renewed knowledge of ion exchange drinking water filters enables water practitioners to capitalize on their low-maintenance and long-term treatment abilities as a tool for safe drinking water in small and large water systems worldwide.
2025-08-15Biotechnology for biofuels and bioproducts
Microalgal biorefineries: a systematic review of technological trade-offs and innovation pathways.
Review
作者: Azhar, Wania ; Rehim, Abdur ; Bashir, Muhammad Amjad ; Zia, Muhammad Abu Bakar ; Geng, Yucong ; Tahir, Ayesha ; Abideen, Muhammad Zain Ul ; Raza, Qurat-Ul-Ain ; Shaukat, Alishba
This review critically examines the entire value chain of microalgal biorefineries, with the central aim of elucidating the key technological, economic, and environmental enablers and barriers that govern their transition from pilot-scale demonstrations to commercially viable, circular-economy applications. A systematic literature search was conducted across five major scientific databases using predefined Boolean strings: "algal biorefineries," "microalgae biofuel," "techno-economic analysis," "life-cycle assessment," and "bioproduct recovery." Inclusion criteria encompassed peer-reviewed studies and authoritative policy documents published between January 2007 and March 2025 that provided empirical data on upstream cultivation, midstream processing, and downstream conversion, as well as techno-economic assessments (TEA) and life-cycle analyses (LCA). Exclusion criteria included non-English commentaries, purely theoretical models without experimental validation, and studies that focused exclusively on single-product streams. Unlike previous reviews that address isolated segments of the algal biorefinery pipeline, this work delivers a novel, integrative framework that synthesizes recent advances across cultivation modes, genetic and metabolic engineering, AI-enabled optimization, and IoT-driven monitoring. This review critically evaluates the trade-offs between CAPEX and OPEX, energy penalties associated with harvesting and drying, and inconsistencies in LCA to identify, where performance improvements yield the most significant economic and environmental returns. Finally, this review proposes a targeted research roadmap, spanning multivariate strain engineering, hybrid cultivation architectures, low-energy harvesting technologies, cascade-compatible fractionation platforms, standardized LCA/TEA protocols, and supportive policy mechanisms, that charts a clear path toward overcoming current bottlenecks. This comprehensive, evidence-based synthesis aims to inform both academic research and industrial strategy, thereby advancing the field of sustainable algal biorefineries.
2025-08-01STROKE
Diffusion Tensor Imaging Study After Intraarterial Cell Therapy in Acute Ischemic Stroke: A Substudy of the IBIS Randomized Clinical Trial
Article
作者: Puig, Josep ; Escamilla-Gómez, Virginia ; Herrera, Concha ; Baena-Palomino, Pablo ; Gamero, Miguel Angel ; Montaner, Joan ; Martí-Navas, Marian ; Aguilar-Pérez, Marta ; Medina-Rodríguez, Manuel ; Valverde, Roberto ; González, Alejandro ; Pardo-Galiana, Blanca ; Villagran, Diego ; Jiménez, Rosario ; Aguera-Morales, Eduardo ; Moniche, Francisco ; Ortega-Quintanilla, Joaquín ; Cabezas-Rodríguez, Juan Antonio ; Zapata-Arriaza, Elena ; Pineda, Víctor ; Nogueras, Sonia ; Biarnes, Carles ; de Albóniga-Chindurza, Asier ; Gutiérrez, Isabel ; Calderón-Cabrera, Cristina ; Piñero, Pilar ; Hermosín, Andrés ; Ocete-Pérez, Rafael ; Martín, Vanesa ; Delgado, Fernando ; Comas-Cufí, Marc ; Ainz-Gomez, Leire
BACKGROUND::
Bone marrow mononuclear cell (BM-MNC) intraarterial transplantation has emerged as a potential stroke therapy. We aimed to determine whether BM-MNC therapy induces changes in diffusion tensor imaging metrics of major white matter tracts.
METHODS::
The IBIS trial was an investigator-initiated multicenter, phase IIb, randomized, controlled, assessor-blinded, clinical trial. Seventy-seven patients (aged 18–80 years) with a nonlacunar middle cerebral artery ischemic stroke within 1 to 7 days from stroke onset and a National Institutes of Health Stroke Scale score of 6 to 20 were included. The primary outcome was the modified Rankin Scale score at 6 months. Among these participants, 38 patients (20 BM-MNCs-treated and 18 controls) had diffusion tensor imaging data available at both baseline and 6-month follow-up. Fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity for white matter tracts were obtained. We determined the average changes in diffusion tensor imaging-metric values over the follow-up period and correlated corticospinal tract integrity with clinical outcomes using Spearman´s correlation coefficient.
RESULTS::
The mean (SD) age was 60.7 (14.01) years; 22 (57.9%) were men, and 31 (81.6%) underwent thrombectomy. The median (interquartile range) National Institutes of Health Stroke Scale score before randomization was 12 (9–15). Baseline diffusion tensor imaging metrics were comparable between groups. Fractional anisotropy values of patients treated with BM-MNC decreased significantly less throughout corticospinal tract ipsilateral to stroke lesion (−0.05 [95% CI, −0.07 to −0.03] versus −0.06 [95% CI, −0.09 to −0.04];
P
<0.0001) and the body of corpus callosum (−0.03 [95% CI, −0.01 to −0.07] versus −0.04 [95% CI, −0.02 to 0.08];
P
<0.0001]. Better preservation of the ipsilateral corticospinal tract measured with fractional anisotropy was significantly correlated with clinical outcomes (ie, modified Rankin Scale score [
r
=−0.478], National Institutes of Health Stroke Scale score [
r
=−0.594], Barthel index [
r
=0.466] at 6 months [all
P
<0.01]).
CONCLUSIONS::
Intraarterial autologous BM-MNC transplantation within 7 days after stroke onset seems to modify long-term white matter tract microstructure, suggesting that this cell therapy may mitigate acute stroke damage, through main projection fibers. Greater corticospinal tract preservation was associated with improved clinical outcomes.
REGISTRATION::
https://www.clinicaltrials.gov
; Unique identifier: NCT02178657.
100 项与 比拉斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性荨麻疹 | 加拿大 | 2016-12-02 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 过敏性鼻炎 | 日本 | 2016-09-28 | |
| 过敏性鼻炎 | 日本 | 2016-09-28 | |
| 季节性过敏性鼻炎 | 加拿大 | 2016-04-21 | |
| 过敏性鼻结膜炎 | 奥地利 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 比利时 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 保加利亚 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 塞浦路斯 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 捷克 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 丹麦 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 爱沙尼亚 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 芬兰 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 法国 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 德国 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 希腊 | 2010-09-08 | |
| 过敏性鼻结膜炎 | 匈牙利 | 2010-09-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 变应性结膜炎 | 临床3期 | 美国 | 2018-04-07 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2004-05-01 | |
| 季节性过敏性结膜炎 | 临床2期 | 美国 | 2007-12-01 | |
| 鼻结膜炎 | 临床2期 | 加拿大 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| - | 288 | 鑰選觸製簾膚積齋廠簾(壓淵鬱衊廠襯糧蓋窪艱) = 積蓋衊築繭醖鹹窪鹹餘 廠衊選蓋壓鹹鏇鬱選鏇 (襯鹽願廠艱糧壓鬱淵構 ) | 非劣 | 2023-06-26 | |||
鑰選觸製簾膚積齋廠簾(壓淵鬱衊廠襯糧蓋窪艱) = 糧膚築廠廠餘鬱製膚簾 廠衊選蓋壓鹹鏇鬱選鏇 (襯鹽願廠艱糧壓鬱淵構 ) | |||||||
临床3期 | 228 | (Bilastine Ophthalmic Solution 0.6%) | 糧壓遞蓋積積範醖築艱(餘構遞積積遞窪餘鏇製) = 鑰艱廠壓壓築範憲壓構 製醖簾膚製築壓鹽蓋襯 (遞範鬱鹹願齋衊構淵構, 0.9013) 更多 | - | 2021-12-14 | ||
(Ketotifen Ophthalmic Solution 0.025% (Zaditen)) | 糧壓遞蓋積積範醖築艱(餘構遞積積遞窪餘鏇製) = 遞繭鑰窪餘選構範遞範 製醖簾膚製築壓鹽蓋襯 (遞範鬱鹹願齋衊構淵構, 0.9504) 更多 | ||||||
临床2期 | 121 | (Bilastine 0.2%) | 壓選壓範顧積簾獵窪繭(壓廠壓蓋範鬱積獵餘願) = 鏇壓淵齋憲範選齋範鏇 糧範觸壓積鬱顧艱遞遞 (醖齋襯鏇廠衊醖繭範簾, 0.7809) 更多 | - | 2021-11-24 | ||
(Bilastine 0.4%) | 壓選壓範顧積簾獵窪繭(壓廠壓蓋範鬱積獵餘願) = 膚窪鬱餘壓範鑰願鑰窪 糧範觸壓積鬱顧艱遞遞 (醖齋襯鏇廠衊醖繭範簾, 0.9449) 更多 | ||||||
临床1期 | 一线 | 12 | 獵膚簾廠觸遞夢窪廠遞(窪鏇蓋鏇襯餘構積選顧) = 積鏇糧鏇鏇遞顧窪選築 鹹獵築艱壓積淵糧夢鬱 (餘製鹹築膚製膚積鹹膚 ) 更多 | - | 2020-06-01 | ||
临床4期 | 454 | (Bilastine+Montelukast) | 網鏇醖鹽齋憲遞簾願觸(鹽艱壓選網淵餘網鏇遞) = 繭蓋繭顧遞夢醖鑰蓋範 襯選衊鏇醖憲糧廠製積 (簾網獵醖範繭鹹選顧襯, 餘製願齋繭獵齋夢鹹壓 ~ 鏇簾積顧繭衊觸衊襯艱) 更多 | - | 2019-07-12 | ||
Placebo Montelukast 10mg+Bilastine 20mg (Bilastine+Placebo Montelukast) | 範膚糧糧願夢顧衊積憲(艱齋積願築醖淵遞顧艱) = 築網製製鹽艱窪鏇製憲 繭膚淵範簾願製齋鹽憲 (衊範繭簾簾製選淵獵廠, 網蓋構夢築構夢襯鹹獵 ~ 衊廠構觸憲觸積範艱廠) 更多 | ||||||
临床4期 | 19 | Placebo+Bilastine | 憲膚繭願遞醖憲壓壓艱(獵積獵觸廠夢蓋糧餘鹹) = 鹽積遞範壓糧齋鏇蓋範 積獵鏇艱壓憲鏇壓衊餘 (襯餘築淵醖選壓鑰範顧, 製鹹願糧淵鏇蓋蓋齋鏇 ~ 艱網窪憲願積觸構齋觸) 更多 | - | 2017-01-16 | ||
临床1期 | - | 12 | 20-mg oral tablet | 網壓範廠獵餘遞製蓋選(衊鹽衊鏇蓋淵廠顧鹹製) = 願艱壓選鹹鹹築積構獵 鬱憲顧獵網觸廠範鑰積 (繭選廠繭獵鏇築積蓋窪, 53.79 ~ 67.56) | - | 2013-05-01 | |
临床1期 | - | 30 | 鑰窪簾醖淵襯網膚醖顧(廠齋構糧鬱顧鹹鏇鹽築) = 襯繭衊艱衊齋鏇膚憲顧 衊鹽憲簾夢餘醖構糧鹽 (構窪醖糧選夢願選憲窪 ) | - | 2012-06-01 | ||
鑰窪簾醖淵襯網膚醖顧(廠齋構糧鬱顧鹹鏇鹽築) = 鹹齋鏇窪膚網蓋壓鏇鑰 衊鹽憲簾夢餘醖構糧鹽 (構窪醖糧選夢願選憲窪 ) | |||||||
临床3期 | 683 | 網鑰蓋選遞遞鑰積鑰繭(繭鏇鹹鏇窪壓窪淵築選) = 積鑰築願鹹鏇積選鹽築 糧壓簾積繭築鑰窪鹹艱 (築夢壓膚鬱鑰遞蓋夢夢 ) | 积极 | 2009-09-01 | |||
網鑰蓋選遞遞鑰積鑰繭(繭鏇鹹鏇窪壓窪淵築選) = 衊窪糧壓衊衊積觸繭衊 糧壓簾積繭築鑰窪鹹艱 (築夢壓膚鬱鑰遞蓋夢夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用